Douglas Smith, MD

Professional Titles

• Co-director, Clinical Research Operations for the Division of Hematologic Malignancies

Primary Academic Title

Professor of Oncology

Background

Centers and Institutes

Sidney Kimmel Comprehensive Cancer Center

Clinical Trial Keywords

AMl; CML; MDS; Acute and Chronic Leukemias; Myeloid Disorders and Bone Marrow Malignancies

Research Interests

Drug Development for Patients with Acute and Chronic Leukemias

Research Summary

Dr. Smith’s research focuses on taking new and promising laboratory insights and developing them into biology-based treatment approaches for patients with AML, CML, and MDS.  He has helped to translate numerous new therapies into the clinic, including differentiation-based strategies; targeted, small-molecule inhibitors of signal transduction pathways (FLT3-ITD, raf kinase, ras kinase, and bcr-abl); agents that alter cell cycle and DNA-damage repair; and immunomodulatory approaches. Dr. Smith’s work integrates biologic correlative studies and biomarkers along with molecular monitoring for minimal residual disease to help determine the ultimate impact of the novel treatments.

PubMed

https://www.ncbi.nlm.nih.gov/myncbi/b.smith.1/bibliography/40365056/public/?sort=date

Selected Publications

• Smith BD, Jones RJ, Cho E, Kowalski J, Karp JE, Gore SD, Vala M, Meade B, Baker SD, Zhao M, Piantadosi S, Zhang Z, Blumenthal G, Warlick ED, Brodsky RA, Murgo A, Rudek MA, Matsui WH. Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk Research. 2011;35(1):87-94. PMCID: PMC3033102

• Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, Biedryzycki B, Harding TC, Tu, GH, Jones RJ, Hege K, Levitsky HI.  K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate. Clin Cancer Res. 2010;16(1):338-47. PMCID: PMC2804932

• Cortes JE, Smith BD, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, Pollyea DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Shaik MN, Laird AD, O'Connell A, Chan G, Schroeder MA.  Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.  Am J Hematol. 2018; 93(11):1301-1310. doi: 10.1002/ajh.25238.  PMID: 30074259.

• Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Jedrzejczak WW, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD.  Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011;117(12):3294-301. PMCID: PMC3069671

• Zeidan AM, Knaus HA, Robinson TM, Towlerton AM, Warren EH, Zeidner JF, Blackford AL, Duffield AS, Rizzieri D, Frattini MG, Levy YM, Schroeder MA, Ferguson A, Sheldon KE, DeZern AE, Gojo I, Gore SD, Streicher H, Luznik L, Smith BD. A mulit-center Phase 1 trial of ipilimumab in Patients with myelodysplastic syndromes following hypomethylating agent failure.  Clin Cancer Res. 2018;24(15):3519-3527. Epub 2018. PMID: 29716921

Honors

• Membership, Miller Coulson Academy for Excellence in Clinical Care, 1/1/20
• Teaching Award in Clinical Science, Sidney Kimmel Comprehensive Cancer Center, 1/1/19
• Teaching Award in Clinical Science, Sidney Kimmel Comprehensive Cancer Center, 1/1/15
• NCI/NIH Cancer Clinical Investigator Team Leadership Award, 1/1/12
• Teaching Award in Clinical Science, Sidney Kimmel Comprehensive Cancer Center, 1/1/10
• Osler Housestaff Teaching Award, Department of Medicine, 1/1/09
• Osler Housestaff Teaching Award, Department of Medicine, 1/1/06

Memberships

• American Society of Hematology
• American Society of Clinical Oncology
• American Association for Cancer Research

Professional Activities

• AA-MDS International Foundation, Medical Advisory Board, 1/1/13
• Johns Hopkins Medicine Institutional Review Board 2, Chair, 1/1/18